Market capitalization | $7.65m |
Enterprise Value | $2.24m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.11 |
P/S ratio (TTM) P/S ratio | 0.38 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 32.45% |
Revenue (TTM) Revenue | $19.96m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
2 Analysts have issued a Carisma Therapeutics forecast:
2 Analysts have issued a Carisma Therapeutics forecast:
Mar '25 |
+/-
%
|
||
Revenue | 20 20 |
32%
32%
|
|
Gross Profit | 17 17 |
70%
70%
|
|
EBITDA | -49 -49 |
39%
39%
|
EBIT (Operating Income) EBIT | -52 -52 |
39%
39%
|
Net Profit | -51 -51 |
37%
37%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in 2016 and is headquartered in Philadelphia, PA.
Head office | United States |
CEO | Steven Kelly |
Employees | 46 |
Founded | 2016 |
Website | www.carismatx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.